Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Vestibular schwannoma

Vestibular schwannoma

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Vestibular schwannoma

5 trials tracked for Vestibular schwannoma.

5Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 3 Phase 1 1 Other / NA 1
  1. Phase 2 Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560 Completed
  2. Phase 2 Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed
  3. Phase 2 Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Completed
  4. Phase 1 Concentration and Activity of Lapatinib in Vestibular Schwannomas Completed
  5. N/A Recovery of Visual Acuity in People With Vestibular Deficits Completed

Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Transcriptome-wide meta-analysis identifies over 1,095 differentially expressed genes in vestibular schwannoma
Oncology Meta-analysis
Transcriptome-wide meta-analysis identifies over 1,095 differentially expressed genes in vestibular schwannoma Gene Analysis Identifies Potential Targets for Vestibular Schwannoma
This meta-analysis of four independent microarray datasets identifies more than 3,200 genes and 1,095 significantly differentially expressed…
A large-scale gene analysis identifies over 1,000 specific genes linked to vestibular schwannoma that may offer new paths for future treatme…
Jul 12, 2026
Repeat microsurgery for recurrent vestibular schwannoma achieves gross total resection but increases facial nerve deterioration risk to 43%
Oncology Meta-analysis
Repeat microsurgery for recurrent vestibular schwannoma achieves gross total resection but increases facial nerve deterioration risk to 43% Repeat surgery for recurrent tumors offers control but higher risks than first surgery
This systematic review and meta-analysis evaluates repeat microsurgical resection versus primary surgery in 359 patients with recurrent vest…
A review of 359 patients found repeat surgery controls recurrent tumors well but carries higher risks of nerve damage and fluid leaks compar…
May 30, 2026